A Clinical Trial Evaluating Diets for IBS - Trial NCT05831306
Access comprehensive clinical trial information for NCT05831306 through Pure Global AI's free database. This phase not specified trial is sponsored by Beth Israel Deaconess Medical Center and is currently Recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beth Israel Deaconess Medical Center
Timeline & Enrollment
N/A
Jul 21, 2021
Dec 31, 2023
Primary Outcome
Abdominal Pain Intensity
Summary
Diet and lifestyle changes are the recommended first line treatments for symptom relief in
 irritable bowel syndrome (IBS). Currently the only diet that is widely recommended and for
 which there is good evidence of efficacy in IBS is one low in fermentable oligosaccharides,
 disaccharides, monosaccharides, and polyols (low-FODMAP). While effective, the Low-FODMAP
 diet is burdensome and costly to patients and in clinical practice adherence to FODMAP
 restriction is less than optimal. Further, patients who respond to a FODMAP restriction often
 are reluctant to reintroduce more FODMAPs into their diet, which may deprive them of foods,
 particularly fruits and vegetables with important health benefits. Therefore, there is a need
 for other dietary interventions for IBS that are less burdensome to patients. This clinical
 trial assesses the efficacy of two dietary interventions.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05831306
Non-Device Trial